ECSP23073404A - 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek - Google Patents
3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mekInfo
- Publication number
- ECSP23073404A ECSP23073404A ECSENADI202373404A ECDI202373404A ECSP23073404A EC SP23073404 A ECSP23073404 A EC SP23073404A EC SENADI202373404 A ECSENADI202373404 A EC SENADI202373404A EC DI202373404 A ECDI202373404 A EC DI202373404A EC SP23073404 A ECSP23073404 A EC SP23073404A
- Authority
- EC
- Ecuador
- Prior art keywords
- dihydro
- naphthyridin
- diones
- mek inhibitors
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a un compuesto de la Fórmula I [IMAGEN ADJUNTA] o una sal aceptable desde el punto de vista farmacéutico de este, en donde R1, R2, R3 y R4 son como se definen en la presente. La invención se refiere además a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos y usos de dichos compuesto, sales y composiciones para el tratamiento del crecimiento celular anormal, que incluye cáncer, en un sujeto que lo necesita. La invención se refiere además a formas sólidas de 8-((2-fluoro-4-(metiltio)fenil)amino)-2-(2-hidroxietoxi)-7-metil-3,4-dihidro-2,7-naftiridin-1,6(2H,7H)-diona.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168456P | 2021-03-31 | 2021-03-31 | |
| US202263309346P | 2022-02-11 | 2022-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23073404A true ECSP23073404A (es) | 2023-10-31 |
Family
ID=81308057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202373404A ECSP23073404A (es) | 2021-03-31 | 2023-09-27 | 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11802127B2 (es) |
| EP (1) | EP4313981B1 (es) |
| JP (1) | JP7466795B2 (es) |
| KR (1) | KR102681641B1 (es) |
| AU (1) | AU2022250102B2 (es) |
| CA (1) | CA3215293A1 (es) |
| CL (1) | CL2023002896A1 (es) |
| CO (1) | CO2023012682A2 (es) |
| CR (1) | CR20230455A (es) |
| DK (1) | DK4313981T3 (es) |
| DO (1) | DOP2023000208A (es) |
| EC (1) | ECSP23073404A (es) |
| FI (1) | FI4313981T3 (es) |
| HR (1) | HRP20260364T1 (es) |
| IL (1) | IL305978A (es) |
| LT (1) | LT4313981T (es) |
| MX (1) | MX2023011628A (es) |
| PE (1) | PE20232038A1 (es) |
| PT (1) | PT4313981T (es) |
| PY (1) | PY2224252A (es) |
| TW (1) | TWI825637B (es) |
| UY (1) | UY39701A (es) |
| WO (1) | WO2022208391A1 (es) |
| ZA (1) | ZA202309566B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI825637B (zh) * | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| BR112023019861A2 (pt) | 2021-03-31 | 2023-11-07 | Xinthera Inc | Inibidores de mk2 e usos dos mesmos |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005011597A2 (en) | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US7390820B2 (en) | 2003-08-25 | 2008-06-24 | Amgen Inc. | Substituted quinolinone derivatives and methods of use |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| KR100703068B1 (ko) | 2003-12-30 | 2007-04-05 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| SI1761528T1 (sl) * | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka |
| ES2405785T3 (es) | 2005-05-18 | 2013-06-03 | Array Biopharma Inc. | Inhibidores heterocíclicos de MEK y métodos de uso de los mismos |
| WO2007109201A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| CA2645652A1 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| DK2001474T3 (en) | 2006-03-16 | 2016-05-09 | Second Genome Inc | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF |
| CA2645551C (en) | 2006-03-16 | 2016-06-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| US20100298285A1 (en) | 2006-03-16 | 2010-11-25 | Kelly Michael G | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof |
| TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| JP2010520875A (ja) | 2007-03-09 | 2010-06-17 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 |
| JP5363350B2 (ja) * | 2007-03-19 | 2013-12-11 | 武田薬品工業株式会社 | Ｍａｐｋ／ｅｒｋキナーゼ阻害剤 |
| TW200938542A (en) | 2008-02-01 | 2009-09-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| WO2009146034A2 (en) * | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| WO2013033981A1 (zh) * | 2011-09-06 | 2013-03-14 | 江苏先声药物研究有限公司 | 一类2,7-萘啶衍生物及其制备方法和应用 |
| NZ629432A (en) * | 2012-03-14 | 2017-01-27 | Lupin Ltd | Heterocyclyl compounds as mek inhibitors |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| AU2017204973A1 (en) | 2016-01-06 | 2018-07-12 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as EGFR inhibitors |
| WO2019071351A1 (en) | 2017-10-12 | 2019-04-18 | Trillium Therapeutics Inc. | NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| US10358447B2 (en) | 2017-12-04 | 2019-07-23 | Arbutus Biopharma Corporation | Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same |
| WO2020072492A1 (en) | 2018-10-02 | 2020-04-09 | Baruch S. Blumberg Institute | Benzamide derivatives as cgas-sting pathway agonists |
| BR112021005733A2 (pt) | 2018-10-17 | 2021-07-27 | Array Biopharma Inc. | inibidores de proteína tirosina fosfatase |
| EP4233834A3 (en) | 2018-11-20 | 2023-10-25 | NFlection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks |
| CU20210080A7 (es) | 2019-04-02 | 2022-05-11 | Array Biopharma Inc | Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa |
| TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| TW202426436A (zh) | 2020-06-09 | 2024-07-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和病症之化合物 |
| TWI825637B (zh) * | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
-
2022
- 2022-03-28 TW TW111111624A patent/TWI825637B/zh active
- 2022-03-29 UY UY0001039701A patent/UY39701A/es unknown
- 2022-03-30 AU AU2022250102A patent/AU2022250102B2/en active Active
- 2022-03-30 MX MX2023011628A patent/MX2023011628A/es unknown
- 2022-03-30 LT LTEPPCT/IB2022/052952T patent/LT4313981T/lt unknown
- 2022-03-30 CA CA3215293A patent/CA3215293A1/en active Pending
- 2022-03-30 DK DK22716496.9T patent/DK4313981T3/da active
- 2022-03-30 EP EP22716496.9A patent/EP4313981B1/en active Active
- 2022-03-30 CR CR20230455A patent/CR20230455A/es unknown
- 2022-03-30 IL IL305978A patent/IL305978A/en unknown
- 2022-03-30 PT PT227164969T patent/PT4313981T/pt unknown
- 2022-03-30 JP JP2023559675A patent/JP7466795B2/ja active Active
- 2022-03-30 US US17/708,072 patent/US11802127B2/en active Active
- 2022-03-30 WO PCT/IB2022/052952 patent/WO2022208391A1/en not_active Ceased
- 2022-03-30 PE PE2023002752A patent/PE20232038A1/es unknown
- 2022-03-30 KR KR1020237032578A patent/KR102681641B1/ko active Active
- 2022-03-30 FI FIEP22716496.9T patent/FI4313981T3/fi active
- 2022-03-30 HR HRP20260364TT patent/HRP20260364T1/hr unknown
- 2022-03-31 PY PY202202224252A patent/PY2224252A/es unknown
- 2022-12-01 US US18/060,864 patent/US11691973B2/en active Active
-
2023
- 2023-09-18 US US18/469,132 patent/US20240002384A1/en not_active Abandoned
- 2023-09-26 CO CONC2023/0012682A patent/CO2023012682A2/es unknown
- 2023-09-27 EC ECSENADI202373404A patent/ECSP23073404A/es unknown
- 2023-09-28 DO DO2023000208A patent/DOP2023000208A/es unknown
- 2023-09-28 CL CL2023002896A patent/CL2023002896A1/es unknown
- 2023-10-12 ZA ZA2023/09566A patent/ZA202309566B/en unknown
-
2025
- 2025-04-30 US US19/195,259 patent/US20250263411A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23073404A (es) | 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek | |
| CL2021001991A1 (es) | Compuestos 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria cdk2. | |
| CO2021006114A2 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
| MX2022001908A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina. | |
| PY1932509A (es) | Inhibidores de cinasa dependientes de ciclina | |
| CU20190010A7 (es) | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS | |
| DOP2014000055A (es) | Derivados de pirrolopirimidina y purina | |
| UY39303A (es) | Inhibidores de mutación her2 | |
| ECSP22003665A (es) | Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll | |
| PY2253236A (es) | Inhibidores de mutacion de her2 | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| UY28356A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| UY28357A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos | |
| ECSP24038829A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| MX2020013895A (es) | Agentes inhibidores de ask1. | |
| AR125256A1 (es) | 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek | |
| EA202191055A1 (ru) | ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-1Н-ПИРРОЛО[3,4-с]ПИРИДИН-1-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ НРК1 ДЛЯ ЛЕЧЕНИЯ РАКА | |
| CU20140033A7 (es) | Derivados de pirrolopirimidina y purina |